

1. Record Nr.	UNINA9910817984103321
Titolo	COX-2 inhibitor research [[electronic resource] /] / Maynard J. Howardell, editor
Pubbl/distr/stampa	New York, : Nova Science Publishers, c2006
ISBN	1-61668-114-4
Edizione	[1st ed.]
Descrizione fisica	1 online resource (263 p.)
Altri autori (Persone)	HowardellMaynard J
Disciplina	615/.7
Soggetti	Nonsteroidal anti-inflammatory agents Arthritis - Chemotherapy Anti-inflammatory agents
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Cyclooxygenase-2 inhibitor and gastric cancer / Yumin Li, Raaj K. Praseedom, and Andrew Butler et al. -- Prevention and chemoprevention of gastric cancer : dietary habits, Helicobacter pylori and COX-2 inhibitors / Gerardo Nardone and Alba Rocco -- Cyclooxygenases in cancer / Daniela Fodera ... et al. -- Nephrotoxicity of nonsteroidal anti-inflammatory drugs : focus on selective cyclooxygenase-2 (COX-2) inhibitors / Steven G. Coca and Mark A. Perazella -- Are COX-2 inhibitors active on intracellular oxidative processes? A study on in vitro and cellular models / Ange Mouithys-Mickalad et al. -- Theoretical mechanism studies on dual inhibition of human cyclooxygenase-2 and 5-lipoxygenase by diaryl-pyrrolizine derivatives / R. Pouplana, C. Perez, and J. Ruiz -- NSAIDs in animal models of Alzheimer's disease / N.G. Giovannini, C. Scali, and A. Bellucci -- Relevance of COX-2 inhibitors in Alzheimer's disease / Amita Quadros, Laila Abdullah, and Nikunj Patel et al. -- COX. 1-COX.2 simultaneous inhibitory mechanism in gastric injury and COX. 2-COX.3 in small intestine injury / Laudanno Oscar -- Effects of COX-2 inhibitors on brain diseases / Takako Takemiya -- Cyclooxygenase-2 overexpression and the chemopreventive and therapeutic uses of cyclooxygenase inhibitors in lung cancer / Zhongxing Liao et al. -- Safety monitoring of celecoxib and rofecoxib in the New Zealand intensive medicines monitoring programme / David Coutler et al.

